Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease A double-blind crossover trial.

Publisher Website
Google Scholar
Abstract
Fifteen parkinsonian previously untreated with levodopa were treated with daily doses of 200 mg Madopar and randomized to addition of 10 mg selegiline (1-deprenyl) in a double-blind, placebo-controlled, crossover trial. According to the patients own evaluations 6 reported additional therapeutic effect from selegiline to Madopar; 2 reported possible additional effect, whereas a further 6 reported no improvement; 1 did not complete the trial. Statistically significant positive therapeutic effect of selegiline could not be found on Webster''s rating scale or on a sensimotoric test designed for parkinosonian disabilities. Side effects of selegiline were minimal. It is concluded that selegiline may be of sone value in addition to levodopa in early treatment of parkinsonian patients, but positive therapeutic effect has to be tested individually. Even in these patients the additional therapeutic effectof selegiline to levodopa seems to be quantitatively small.

This publication has 7 references indexed in Scilit: